Using claims data alone can jeopardize a drug’s launch, especially in rare diseases. Fill the blind spots with better data using this essential guide.
Hundreds of rare disease treatments have entered the market over the past decade—thanks largely to a combination of government incentives, strong urging from patient advocacy groups and advances in cell and gene therapies.
But despite the supportive landscape for rare disease therapies, pharma companies still struggle to launch on time, if at all. Is the data to blame?
In this white paper, you’ll learn:
Offered Free by: Komodo Health
See All Resources from: Komodo Health